Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would ...

The U.S. Food and Drug Administration announced that it has placed Sarepta Therapeutics' (SRPT) investigational gene therapy trials for limb-girdle muscular dystrophy on ...

(Reuters) -Sarepta Therapeutics said on Monday its new experimental drug for Duchenne muscular dystrophy (DMD) was far more effective in increasing levels of a key protein than its bestselling ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold requested by the EU drug regulator, European Medicines Agency (EMA), on ...

Sarepta, Roche seek to resume Elevidys trials Apr. 04, 2025 9:28 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock , RHHBY Stock , RHHBF Stock By: Dulan Lokuwithana , SA News Editor 1 Comment Play ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a patient taking it died. ... 3 Clinical Trials Halted .

Sarepta Therapeutics Inc. gained about $2.5 billion of stock market value after an early stage trial of a gene therapy showed promise in its ability to treat patients with Duchenne muscular dystrophy.

Sarepta Therapeutics said on Monday its new experimental drug for Duchenne ... Based on results from the trial for SRP-5051, Sarepta has requested for a meeting with the FDA which is expected to ...

(Reuters) -Sarepta Therapeutics said on Monday its new experimental drug for Duchenne muscular dystrophy (DMD) was far more effective in increasing levels of a key protein than its bestselling ...